ISDA

Deposition Date 2023-07-23

Release Date 2023-11-08

Last Version Date 2023-11-08

Entry Detail

PDB ID:

8PXN

Keywords:

TRANSCRIPTION

Title:

N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH (1R,1'R)-7,7'-(ethane-1,2-diylbis(oxy))bis(1,3-dimethyl-1,3-dihydro-2H-benzo[d]azepin-2-one)

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.95 Å

R-Value Free:

0.27

R-Value Work:

0.19

Space Group:

P 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Bromodomain-containing protein 4
Gene (Uniprot):BRD4
Chain IDs:A, B, C, D
Chain Length:127
Number of Molecules:4
Biological Source:Homo sapiens

UniProt ID:O60885 Pfam ID:PF00439

Ligand Molecules

EDO

ZTT

Primary Citation

Design and Characterization of 1,3-Dihydro-2 H -benzo[ d ]azepin-2-ones as Rule-of-5 Compliant Bivalent BET Inhibitors.

Bamborough, P, Chung, C.W, Goodwin, N.C, Mitchell, D.J, Neipp, C.E, Phillipou, A, Preston, A, Prinjha, R.K, Soden, P.E, Watson, R.J, Demont, E.H.Show

Acs Med.Chem.Lett. 14 1231 1236 (2023)

PMID: 37736196 DOI: 10.1021/acsmedchemlett.3c00242

Abstact

The 1,3-dihydro-2H-benzo[d]azepin-2-ones are potent and ligand-efficient pan-BET bromodomain inhibitors. Here we describe the extension of this template to exploit a bivalent mode of action, binding simultaneously to both bromodomains. Initially the linker length and attachment vectors compatible with bivalent binding were explored, leading to the discovery of exceptionally potent bivalent BET inhibitors within druglike rule-of-5 space.

Legend

Protein

Chemical

Disease

Primary Citation of related structures